Asset
ENTINOSTAT
SYNDAX PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00750698 | phase2 | terminated | 2008-08-01 | 2010-05-01 | Syndax Pharmaceuticals | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib |
| NCT00866333 | phase2 | terminated | 2009-04-13 | 2013-02-08 | Syndax Pharmaceuticals | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma |
| NCT00754312 | phase1 | terminated | 2008-06-01 | 2009-02-28 | Syndax Pharmaceuticals | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer |
| NCT03192111 | phase1 | completed | 2017-07-27 | 2017-11-23 | Syndax Pharmaceuticals | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function |
| NCT02922933 | phase1 | completed | 2016-10-25 | 2017-04-19 | Syndax Pharmaceuticals | A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects |
FDA applications (0)
This company has no applications containing this asset.